EC Number   |
Inhibitors |
Structure |
|---|
   4.6.1.2 | 17beta-estradiol |
decreases enzyme activity in immature rats, while the amount of sGC alpha subuit increases, estrogen receptor-dependent effects, overview |
   |
| 4.6.1.2 | 1H-(1,2,4)-oxadiazole-(4,3-a)quinoxalin-1-one |
- |
|
| 4.6.1.2 | 1H-(1,2,4)oxadiazole(4,3-a)quinoxalin-1-one |
- |
|
| 4.6.1.2 | 1H-(1,2,4)oxadiazole(4,3-a)quinoxalin-1one |
0.1 mM, complete inhibition |
|
| 4.6.1.2 | 1H-(1,2,4)oxadiazole(4,3-a)quinoxalin-1one |
- |
|
| 4.6.1.2 | 1H-(1,2,4)oxadiazole(4,3-a)quinoxalin-1one |
specific inhibitor of sGC |
|
| 4.6.1.2 | 1H-[1,2,4] oxadiazole [4,3-a] quinoxalin-1-one |
effectively blocks guanylyl cyclase activity in response to low O2 levels |
|
| 4.6.1.2 | 1H-[1,2,4]-oxadiazole[4,3-a]quinoxalin-1-one |
i.e. ODQ, a highly selective sGC inhibitor; i.e. ODQ, a highly selective sGC inhibitor |
|
| 4.6.1.2 | 1H-[1,2,4]oxadiazolo [4,3,-a]quinoxalin-1-one |
i.e. ODQ, in vivo treatment with the sGC inhibitors ODQ does not decrease plasmatic and jejunal cGMP levels, nor does it influence the change in electrical field-induced relaxation; i.e. ODQ, in vivo treatment with the sGC inhibitors ODQ does not decrease plasmatic and jejunal cGMP levels, nor does it influence the change in electrical field-induced relaxation |
|
| 4.6.1.2 | 1H-[1,2,4]oxadiazolo [4,3,-a]quinoxalin-1-one |
i.e. ODQ |
|
